KATIE LACY: Open Payments
NPI 1710469986 · DUBLIN, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,559 in 73 payments from 11 companies in 2025. Trend: 2023 $716 · 2024 $793 · 2025 $1,559
Food & beverage: $1,559
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 11 | $307 |
| AstraZeneca Pharmaceuticals LP | 14 | $281 |
| GENZYME CORPORATION | 18 | $270 |
| Novartis Pharmaceuticals Corporation | 7 | $186 |
| Regeneron Healthcare Solutions, Inc. | 5 | $147 |
| Optinose US, Inc. | 6 | $146 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $121 |
| Cycle Pharmaceuticals Inc | 2 | $42 |
| Amgen Inc. | 2 | $28 |
| CSL Behring | 1 | $17 |
Products named: DUPIXENT, NUCALA, Xhance, FASENRA, NEFFY, Rhapsido, AIRSUPRA, TEZSPIRE.
Industry payments across OH — which companies pay providers there.
